Détail de l'auteur
Documents disponibles écrits par cet auteur
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) Mettre toutes les notices dans le panier Faire une suggestion Ajouter un critère de recherche
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies
Hou C, Durrleman C, Periou B, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2020
Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-alpha signalling
Melki I, Devilliers H, Gitiaux C, et al.
Rheumatology (Oxford, England), 2019
The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis
Aussy A, Fréret M, Gallay L, et al.
Arthritis & rheumatology (Hoboken, N.J.), 2019
A child with severe juvenile dermatomyositis treated with ruxolitinib
Aeschlimann FA, Aeschlimann FA, Fremond ML, et al.
Brain : a journal of neurology, 2018, 141, 11
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies
Mariampillai K, Mariampillai K, Granger B, et al.
JAMA Neurology, 2018, 75, 12, p 1528
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis
Aouizerate J, De Antonio M, Bader-Meunier B, et al.
Rheumatology (Oxford, England), 2018, 57, 5, p 873
Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies
Mauhin W, Mariampillai K, Allenbach Y, et al.
Joint, bone, spine : revue du rhumatisme, 2017, 85, 3, p 375
High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
Allenbach Y, Keraen J, Bouvier AM, et al.
Brain : a journal of neurology, 2016, 139, Pt8, p 2131
Th1 response and systemic treg deficiency in inclusion body myositis
Allenbach Y, Chaara W, Rosenzwajg M, et al.
PLoS ONE, 2014, 9, 3, e88788, p. 1-8
Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies.
Drouot L, Allenbach Y, Jouen F, et al.
Arthritis research and therapy, 2014, 16, 1, R39, p. 1-11
Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies
Musset L, Miyara M, Benveniste O, et al.
Journal of immunology research, 2014, 2014
Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies : Inconstant Exposure to Statin
Allenbach Y, Drouot L, Rigolet A, et al.
Medicine, 2014, 93, 3, p 150
Inflammatory myopathies with anti-ku antibodies: a prognosis dependent on associated lung disease
Rigolet A, Musset L, Dubourg O, et al.
Medicine (Baltimore), 2012, 91, 2, p. 95-102
Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use
Stanciu R, Guiguet M, Musset L, et al.
The Journal of rheumatology, 2012, 39, 9, p 1835
Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy
Benveniste O, Drouot L, Jouen F, et al.
Arthritis and rheumatism, 2011, 63, 7, p. 1961-1971
Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy
Benveniste O, Drouot L, Jouen F, et al.
Arthritis and rheumatism, 2011, 63, 7, p. 1961-1971
